Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BBIO, LLY, GERN, HUM, GH, and represent 20.93% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: HUM, SNDX, ARVN, BSX, SLNO, RLAY, GERN, SMMT, JANX, SVRA.
- Started 24 new stock positions in ABUS, Neumora Therapeutics, ANNX, PEN, SNDX, AKBA, ACRS, FULC, SLRN, ARVN. BHVN, IONS, SMMT, MDGL, RCKT, VERU, JANX, BSX, SVRA, NKTR, SLNO, REPL, HUM, ELDN.
- Reduced shares in these 10 stocks: ASND (-$6.5M), TGTX, ALGN, CI, BNTX, VRDN, GKOS, SWTX, AGIO, .
- Sold out of its positions in ACRV, ADAG, AGIO, ALGN, AMGN, ASND, BCRX, BIIB, BNTX, CI. GKOS, INSM, KURA, LXEO, PACB, QTRX, RVNC, RZLT, SWTX, STAA, SYRS, TGTX, VRDN, PROC.
- Exome Asset Management was a net seller of stock by $-16M.
- Exome Asset Management has $133M in assets under management (AUM), dropping by -10.01%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 59 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 5.1 | $6.8M | +16% | 247k | 27.44 |
|
| Eli Lilly & Co. (LLY) | 4.8 | $6.4M | -21% | 8.2k | 772.00 |
|
| Geron Corporation (GERN) | 4.2 | $5.6M | +72% | 1.6M | 3.60 |
|
| Humana (HUM) | 3.4 | $4.6M | NEW | 18k | 253.71 |
|
| Guardant Health (GH) | 3.4 | $4.5M | +64% | 148k | 30.55 |
|
| Relay Therapeutics (RLAY) | 3.4 | $4.5M | +161% | 1.1M | 4.12 |
|
| Disc Medicine (IRON) | 3.3 | $4.4M | +7% | 69k | 63.40 |
|
| Syndax Pharmaceuticals (SNDX) | 3.2 | $4.2M | NEW | 319k | 13.22 |
|
| Arvinas Ord (ARVN) | 3.1 | $4.2M | NEW | 219k | 19.17 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.1 | $4.1M | +26% | 152k | 27.12 |
|
| Intuitive Surgical Com New (ISRG) | 2.9 | $3.9M | 7.4k | 521.96 |
|
|
| Apellis Pharmaceuticals (APLS) | 2.9 | $3.8M | +19% | 120k | 31.91 |
|
| Bristol Myers Squibb (BMY) | 2.8 | $3.7M | -16% | 65k | 56.56 |
|
| Boston Scientific Corporation (BSX) | 2.7 | $3.6M | NEW | 41k | 89.32 |
|
| Natera (NTRA) | 2.7 | $3.6M | 23k | 158.30 |
|
|
| Soleno Therapeutics (SLNO) | 2.6 | $3.5M | NEW | 77k | 44.95 |
|
| Scholar Rock Hldg Corp (SRRK) | 2.5 | $3.3M | -41% | 77k | 43.22 |
|
| Nuvalent Inc-a (NUVL) | 2.4 | $3.2M | +103% | 41k | 78.51 |
|
| Cytokinetics Com New (CYTK) | 2.3 | $3.1M | +12% | 66k | 47.04 |
|
| Blueprint Medicines (BPMC) | 2.1 | $2.8M | -13% | 32k | 87.22 |
|
| Gilead Sciences (GILD) | 2.1 | $2.7M | -40% | 30k | 92.37 |
|
| Summit Therapeutics (SMMT) | 1.7 | $2.3M | NEW | 130k | 17.84 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.7 | $2.3M | 138k | 16.75 |
|
|
| Edgewise Therapeutics (EWTX) | 1.6 | $2.2M | +36% | 82k | 26.70 |
|
| Janux Therapeutics (JANX) | 1.6 | $2.1M | NEW | 40k | 53.54 |
|
| Savara (SVRA) | 1.6 | $2.1M | NEW | 700k | 3.07 |
|
| Ionis Pharmaceuticals (IONS) | 1.6 | $2.1M | NEW | 61k | 34.96 |
|
| Penumbra (PEN) | 1.6 | $2.1M | NEW | 9.0k | 237.48 |
|
| Rocket Pharmaceuticals (RCKT) | 1.5 | $2.0M | NEW | 160k | 12.57 |
|
| Akero Therapeutics (AKRO) | 1.4 | $1.9M | -11% | 69k | 27.82 |
|
| Dr Reddys Labs Adr (RDY) | 1.4 | $1.9M | +223% | 118k | 15.79 |
|
| Beigene Sponsored Adr | 1.4 | $1.8M | -34% | 10k | 184.71 |
|
| 89bio (ETNB) | 1.3 | $1.8M | -25% | 225k | 7.82 |
|
| Tarsus Pharmaceuticals (TARS) | 1.2 | $1.6M | -38% | 28k | 55.37 |
|
| Karyopharm Therapeutics Note 3.000%10/1 | 1.2 | $1.6M | 2.0M | 0.78 |
|
|
| Pliant Therapeutics (PLRX) | 1.0 | $1.4M | -30% | 104k | 13.17 |
|
| Fulcrum Therapeutics (FULC) | 1.0 | $1.3M | NEW | 284k | 4.70 |
|
| Stoke Therapeutics (STOK) | 0.9 | $1.2M | -35% | 113k | 11.03 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.9 | $1.2M | -20% | 38k | 32.54 |
|
| Tectonic Therapeutic (TECX) | 0.9 | $1.2M | -28% | 26k | 46.17 |
|
| Alvotech Ordinary Shares (ALVO) | 0.9 | $1.2M | 90k | 13.23 |
|
|
| Vyne Therapeutics (VYNE) | 0.9 | $1.2M | 353k | 3.35 |
|
|
| Eledon Pharmaceuticals (ELDN) | 0.8 | $1.1M | NEW | 256k | 4.12 |
|
| Biohaven (BHVN) | 0.8 | $1.1M | NEW | 28k | 37.35 |
|
| Gossamer Bio (GOSS) | 0.7 | $993k | +134% | 1.1M | 0.90 |
|
| Aclaris Therapeutics (ACRS) | 0.7 | $966k | NEW | 389k | 2.48 |
|
| Annexon (ANNX) | 0.6 | $743k | NEW | 145k | 5.13 |
|
| Female Health (VERU) | 0.6 | $740k | NEW | 1.1M | 0.66 |
|
| Acelyrin (SLRN) | 0.6 | $736k | NEW | 234k | 3.14 |
|
| Replimune Group (REPL) | 0.5 | $663k | NEW | 55k | 12.11 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.5 | $604k | -39% | 13k | 46.07 |
|
| Nektar Therapeutics (NKTR) | 0.4 | $575k | NEW | 618k | 0.93 |
|
| Aprea Therapeutics Com New (APRE) | 0.3 | $420k | -6% | 128k | 3.28 |
|
| Akebia Therapeutics (AKBA) | 0.3 | $391k | NEW | 206k | 1.90 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $305k | NEW | 987.00 | 308.57 |
|
| Leap Therapeutics Com New (LPTX) | 0.2 | $295k | 103k | 2.88 |
|
|
| Mersana Therapeutics (MRSN) | 0.2 | $250k | -85% | 173k | 1.44 |
|
| Neumora Therapeutics Call Call Option | 0.2 | $207k | NEW | 600.00 | 345.00 |
|
| Arbutus Biopharma (ABUS) | 0.1 | $93k | NEW | 28k | 3.27 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2024 Q4 filed Feb. 14, 2025
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024